At an announcement made earlier today, Merck confirmed its commitment to research and innovation in oncology by contributing a total of $2 million to the Exactis Innovation ‘Personalize My Treatment’ (PMT) initiative.
In addition, the Cancer Research Society (CRS) and the New Brunswick Health Research Foundation (NBHRF) will also contribute $1 million each to help bring innovative precision medicine to Canadians living with cancer.